نتایج جستجو برای: metronomic

تعداد نتایج: 910  

2018
Nengping Zhu Rongsheng Qin Qin Zhang Shaozhi Fu Shanshan Liu Yue Chen Juan Fan Yunwei Han

Metronomic chemotherapy in combination with immunotherapy is an attractive approach in cancer therapy. The purpose of the present study was to investigate the anti-tumor effect of granulocyte-macrophage colony-stimulating factor (GM-CSF) in combination with metronomic paclitaxel (MET PTX) on Lewis lung carcinoma transplanted in mice. In the present study, tumor-bearing mice survival time and tu...

Journal: :Mathematical biosciences and engineering : MBE 2016
Ami B Shah Katarzyna A Rejniak Jana L Gevertz

While chemoresistance in primary tumors is well-studied, much less is known about the influence of systemic chemotherapy on the development of drug resistance at metastatic sites. In this work, we use a hybrid spatial model of tumor response to a DNA damaging drug to study how the development of chemoresistance in micrometastases depends on the drug dosing schedule. We separately consider cell ...

2016
Yusuke Doi Amr S Abu Lila Haruna Matsumoto Tomoko Okada Taro Shimizu Tatsuhiro Ishida

The efficient delivery of nanocarrier-based cancer therapeutics into tumor tissue is problematic. Structural abnormalities, tumor vasculature heterogeneity, and elevated intratumor pressure impose barriers against the preferential accumulation of nanocarrier-based cancer therapeutics within tumor tissues and, consequently, compromise their therapeutic efficacy. Recently, we have reported that m...

Journal: :Molecular therapy : the journal of the American Society of Gene Therapy 2011
Vincenzo Cerullo Iulia Diaconu Lotta Kangasniemi Maria Rajecki Sophie Escutenaire Anniina Koski Valentina Romano Noora Rouvinen Tamara Tuuminen Leena Laasonen Kaarina Partanen Satu Kauppinen Timo Joensuu Minna Oksanen Sirkka-Liisa Holm Elina Haavisto Aila Karioja-Kallio Anna Kanerva Sari Pesonen Petteri T Arstila Akseli Hemminki

Patients with advanced solid tumors refractory to and progressing after conventional therapies were treated with three different regimens of low-dose cyclophosphamide (CP) in combination with oncolytic adenovirus. CP was given with oral metronomic dosing (50 mg/day, N = 21), intravenously (single 1,000 mg dose, N = 7) or both (N = 7). Virus was injected intratumorally. Controls (N = 8) received...

Journal: :Biomaterials 2013
Li-Min Luo Yue Huang Bing-Xiang Zhao Xin Zhao Yu Duan Ruo Du Ke-Fu Yu Ping Song Yang Zhao Xuan Zhang Qiang Zhang

In the present study, we prepared NGR-modified sterically stabilized liposomes containing paclitaxel (NGR-SSL-PTX) in order to evaluate their potential targeting to aminopeptidase N receptors expressed on tumor endothelial cells and the tumor cell surface and its anti-angiogenic activity following metronomic administration. NGR-SSL-PTX was prepared by a thin-film hydration method. The in vitro ...

Journal: :Molecular cancer therapeutics 2014
Kshipra M Gharpure Kevin S Chu Charles J Bowerman Takahito Miyake Sunila Pradeep Selanere L Mangala Hee-Dong Han Rajesha Rupaimoole Guillermo N Armaiz-Pena Tojan B Rahhal Sherry Y Wu J Christopher Luft Mary E Napier Gabriel Lopez-Berestein Joseph M DeSimone Anil K Sood

The purpose of this study was to investigate the antitumor effects of a combination of metronomic doses of a novel delivery vehicle, PLGA-PRINT nanoparticles containing docetaxel, and antiangiogenic mEZH2 siRNA incorporated into chitosan nanoparticles. In vivo dose-finding studies and therapeutic experiments were conducted in well-established orthotopic mouse models of epithelial ovarian cancer...

Journal: :Cancer research 2013
Philip Hahnfeldt Lynn Hlatky Giannoula Lakka Klement

Metronomic chemotherapy, the delivery of doses in a low, regular manner so as to avoid toxic side effects, was introduced over 12 years ago in the face of substantial clinical and preclinical evidence supporting its tumor-suppressive capability. It constituted a marked departure from the classic maximum-tolerated dose (MTD) strategy, which, given its goal of rapid eradication, uses dosing suffi...

2013
Philip Hahnfeldt Lynn Hlatky Giannoula Lakka Klement

Metronomic chemotherapy, the delivery of doses in a low, regular manner so as to avoid toxic side effects, was introduced over 12 years ago in the face of substantial clinical and preclinical evidence supporting its tumorsuppressive capability. It constituted a marked departure from the classic maximum-tolerated dose (MTD) strategy, which, given its goal of rapid eradication, uses dosing suffic...

2015
V. Petry D.M. Gagliato A.I.C. Leal R.J. Arai E. Longo F. Andrade M.D. Ricci J.R. Piato R. Barroso-Sousa P.M. Hoff M.S. Mano

Neoadjuvant chemotherapy has practical and theoretical advantages over adjuvant chemotherapy strategy in breast cancer (BC) management. Moreover, metronomic delivery has a more favorable toxicity profile. The present study examined the feasibility of neoadjuvant metronomic chemotherapy in two cohorts [HER2+ (TraQme) and HER2- (TAME)] of locally advanced BC. Twenty patients were prospectively en...

Journal: :Oncology reports 2011
Sriram Mupparaju Huagang Hou Jean P Lariviere Harold Swartz Youssef Jounaidi Nadeem Khan

Malignant gliomas are aggressive and angiogenic tumors with high VEGF content. Consequently, approaches such as metronomic chemotherapy, which have an anti-angiogenic effect, are being investigated. However, a lack of an appropriate technique that can facilitate the identification of vascular changes during antiangiogenic treatments has restricted therapeutic optimization. We have investigated ...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید